Portal de Periódicos da CAPES

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

2014; Wiley; Volume: 165; Issue: 1 Linguagem: Inglês

10.1111/bjh.12715

1365-2141

Yasuhiro Oki, Hubert H. Chuang, Beth Chasen, Aaron Jessop, Tinsu Pan, Michelle A. Fanale, Bouthaina S. Dabaja, Nathan Fowler, Jorge Romaguera, Luis Fayad, Fredrick B. Hagemeister, Maria Alma Rodriguez, Sattva S. Neelapu, Felipe Samaniego, Larry W. Kwak, Anas Younes,

Lung Cancer Treatments and Mutations

The prognostic value of interim positron emission tomography (PET) was evaluated after 2 cycles of doxorubicin, bleomycin, vinblastin and dacarbazine in classical Hodgkin lymphoma patients (n = 229), based on Deauville criteria. In early stage non-bulky disease, bulky stage II disease, advanced stage low International Prognostic Score (IPS ≤2) and advanced stage (IPS ≥3), 3-year progression-free survival rates in PET2-negative vs. PET2-positive groups were 95·9% vs. 76·9% (P < 0·0018), 83·3% vs. 20·0% (P = 0·017), 77·0% vs. 30·0% (P < 0·001) and 71·0% vs. 44·4%(P = 0·155), respectively. The outcome after positive PET2 was better than previously reported. The results from non-randomized studies of PET2-guided therapy would be valuable with careful interpretation.